Guanghao Su

1.2k citations
35 papers · 984 indexed · h-index 14
Topics
Nanoparticle-Based Drug Delivery (18 papers)Nanoplatforms for cancer theranostics (18 papers)RNA Interference and Gene Delivery (5 papers)
Partner nations
ChinaTaiwanUnited States

In The Last Decade

Guanghao Su

35 papers receiving 976 citations

Peers

Guanghao Su
Comparison fields: 5 of 84
  • Biomedical Engineering 685
  • Biomaterials 537
  • Molecular Biology 301
  • Materials Chemistry 188
  • Pulmonary and Respiratory Medicine 114
Replace Jiwen Qian with:
Jiwen Qian China
Zar Chi Soe South Korea
Wenquan Ou South Korea
Gaizhen Kuang China
Chih‐Sheng Chiang Taiwan
Remon Bazak Egypt
Yongzhi Men China
Shishuai Su China
Dongsik Park South Korea
Dayun Yang China
Guanghao Su relative to Jiwen Qian China Jiwen Qian's profile →
Citations per field
00.5×4.2×
Jiwen Qian · 1×
Citations per year

Countries citing papers authored by Guanghao Su

Since Specialization
Citations

This map shows the geographic impact of Guanghao Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guanghao Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guanghao Su more than expected).

Fields of papers citing papers by Guanghao Su

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guanghao Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guanghao Su. The network helps show where Guanghao Su may publish in the future.

Co-authorship network of co-authors of Guanghao Su

This figure shows the co-authorship network connecting the top 25 collaborators of Guanghao Su. A scholar is included among the top collaborators of Guanghao Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guanghao Su. Guanghao Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 2
2 4
3 4
4 1
5 9
6 19
7 10
8 23
9 47
10 5
11 100
12 30
13 13
14 31
15 227
16 113
17 55
18 23
19 7
20 23

About Guanghao Su

Guanghao Su is a scholar working on Biomaterials, Biomedical Engineering and Polymers and Plastics, having authored 35 papers that have together received 984 indexed citations. Recurring topics across this work include Nanoparticle-Based Drug Delivery (18 papers), Nanoplatforms for cancer theranostics (18 papers) and RNA Interference and Gene Delivery (5 papers). The work is most often cited by research in Biomaterials (537 citations), Biomedical Engineering (685 citations) and Pharmaceutical Science (50 citations). Guanghao Su has collaborated with scholars based in China, Taiwan and United States. Frequent co-authors include Zhenqing Hou, Shefang Ye, Jinyan Lin, Jinyuan Ma, Zhongxiong Fan, Xuan Zhu, Yang Li, Huirong Lin, Dengyue Chen and Liang Song. Their work appears in journals such as ACS Applied Materials & Interfaces, Journal of Colloid and Interface Science and Journal of Controlled Release.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026